CN108185137A - A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs - Google Patents
A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs Download PDFInfo
- Publication number
- CN108185137A CN108185137A CN201810002615.6A CN201810002615A CN108185137A CN 108185137 A CN108185137 A CN 108185137A CN 201810002615 A CN201810002615 A CN 201810002615A CN 108185137 A CN108185137 A CN 108185137A
- Authority
- CN
- China
- Prior art keywords
- egg
- drug
- laying
- poultry
- laying performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 129
- 235000013601 eggs Nutrition 0.000 title claims abstract description 120
- 229940079593 drug Drugs 0.000 title claims abstract description 112
- 230000036750 egg laying performance Effects 0.000 title claims abstract description 32
- 244000144977 poultry Species 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 24
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 24
- 241000756943 Codonopsis Species 0.000 claims abstract description 24
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 24
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 24
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 23
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 23
- 229940107666 astragalus root Drugs 0.000 claims abstract description 22
- 230000012447 hatching Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 25
- 241000207925 Leonurus Species 0.000 claims description 20
- 241000287828 Gallus gallus Species 0.000 claims description 15
- 235000020188 drinking water Nutrition 0.000 claims description 15
- 239000003651 drinking water Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 241000272496 Galliformes Species 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000272201 Columbiformes Species 0.000 claims description 7
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 208000027954 Poultry disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 241000272525 Anas platyrhynchos Species 0.000 claims description 3
- 241000272814 Anser sp. Species 0.000 claims description 3
- 241000286209 Phasianidae Species 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical class CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 240000007890 Leonurus cardiaca Species 0.000 abstract description 3
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical group P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 230000008021 deposition Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 34
- 102000002322 Egg Proteins Human genes 0.000 description 18
- 108010000912 Egg Proteins Proteins 0.000 description 18
- 210000003278 egg shell Anatomy 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 235000013594 poultry meat Nutrition 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 235000013330 chicken meat Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 210000002969 egg yolk Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 235000014590 basal diet Nutrition 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002976 pectoralis muscle Anatomy 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001850 reproductive effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000233855 Orchidaceae Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 235000019779 Rapeseed Meal Nutrition 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000004456 rapeseed meal Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000276489 Merlangius merlangus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- -1 dimethylacetamides Amine Chemical class 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 235000015099 wheat brans Nutrition 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003053 completely randomized design Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Birds (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of drug, preparation method and applications for improving poultry egg laying performance and improving quality of laying eggs, and belong to poultry technical field of pharmaceuticals.The drug of the present invention is by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis, VA, VD3, VE is prepared by weight 15~30: 10~25: 20~25: 0.1~4: 0.5~3: 0.1~3: 0.2~2: 0.5~3.The drug of the present invention is green safe, can not only be obviously improved egg fowl enteron aisle, and nutrition digestion is promoted to absorb, and increases absorption and the deposition of calcium phosphorus, improves the quality of egg, reduces feedstuff-egg ratio, reduce the use of antibiotic；The immunity and oxidation resistance of poultry can also be improved, improves breeder egg laying performance, chick hatching rate and rate of healthy chick.
Description
Technical field
The invention belongs to poultry technical field of pharmaceuticals, and in particular to a kind of to improve poultry egg laying performance and improve quality of laying eggs
Drug, preparation method and application.
Background technology
Egg laying performance and quality of laying eggs are the important indicators in laying hen production, are the embodiments of laying hen economic benefit quality.Production
Egg hydraulic performance decline and quality of laying eggs is low is mainly influenced by following factor：Physiology sex expression (such as age in days, kind factor), time-sharing environment
Factor (such as illumination, temperature, humidity, noise, stress), feed factor (it is with low quality, calcium phosphorus ration is improper, nutritional deficiency
Deng), disease factor etc. (such as virosis, bacterial disease, parasitic disease).There is laying rate of laying hen decline or peak in present various regions
The problems such as duration phase is short, since there are many pathogenic factors of the disease, so comprehensive control measure must be taken.At present,
The disease as caused by disease factor, the most commonly used is drug therapy, but antiviral drugs (such as Ribavirin, amantadine, disease
Malicious spirit) Ministry of Agriculture prohibited use；Various antibacterials and anti-parasite medicine due to being repeatedly used for a long, cause
Pathogenic microorganism to which create drug resistance, reducing curative effect, and medicament residue in animal body in egg, quality
Nuisanceless requirement is not achieved, so as to affect the health of the outlet of poultry product and people.With carrying for people's living standard
Height, the requirement to food is also higher and higher, eggs be people supplement protein most often selection, people for eggs quality and
Mouthfeel requirement is also higher and higher, and more people are ready the egg for outbiding to buy Countryside Egg either free-ranging laying hen production.
Eggshell quality difference is the major issue that domestic fowl farming always exists, and not only reduces egg fowl fanning economics, can also drop
Low egg hatchability increases rate of embryonic death.Eggshell can protect embryo from the adverse effect of external environment.The addition of calcium is to influence
An important factor for embryonic development and eggshell quality.Since check and lopsided egg are easy to infection pathogen, thus eggshell quality
Influence to consumer is also larger.
To improve or improving the laying rate of hen, occur a variety of different drugs and additive in the market.These drugs master
If Western medicine, though can improve the problem of hen laying rate is low, often toxic side effect is big, to hen ingest and health shadow
It rings, even medicament residue is in the internal or egg of chicken, it is impossible to ensure the health of food.
Invention content
For problems of the prior art, the present invention provides a kind of raising poultry egg laying performance and improves quality of laying eggs
Drug, the drug be mainly used for improve laying rate of poultry, improve lay eggs quality, extend egg-laying peak.
In order to reach object above, technical scheme is as follows：
It is a kind of improve poultry egg laying performance drug, by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones,
Bacillus subtilis, VA, VD3, VE by weight 15~30: 10~25: 20~25: 0.1~4: 0.5~3: 0.1~3: 0.2~
2: 0.5~3 are prepared.
On the basis of said program, it is described improve poultry egg laying performance drug by Radix Codonopsis extract, Astragalus Root P.E,
Motherwort, isoflavones, bacillus subtilis, VA, VD3, VE is prepared by weight 20: 22: 23: 2: 2: 0.5: 2: 1.
On the basis of said program, the dosage form of the drug is solid pharmaceutical preparation or liquid preparation.
On the basis of said program, the preparation method of the solid pharmaceutical preparation for improving poultry egg laying performance drug, step
For：
1. the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis are weighed respectively
Bacterium, VA, VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, it is stirred 5~10 minutes, until
Uniformly；
3. weigh isoflavones, bacillus subtilis, VA, VD of formula ratio after crushing3, VE, be stirred 5~10 points
Clock, until uniform；
4. in 3. adding in 2., stir evenly, pack, seal to get.
On the basis of said program, the preparation method of the liquid preparation for improving poultry egg laying performance drug, step
For：
1. the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis are weighed respectively
Bacterium, VA, VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the isoflavones of formula ratio after crushing, add 5 times of amount Tween-80 dissolvings, add 10 times of amount dimethylacetamides
Amine is stirred until homogeneous；
3. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, 10 times of amount propylene glycol are added in, are stirred
Mixing is mixed 5~10 minutes, until uniform；
4. by the bacillus subtilis of formula ratio, VA, VD after crushing3, VE add in 3. in, stir evenly, add in purified water,
To 1000mL.
The drug of raising poultry egg laying performance prepared by the above method is in poultry disease or disease recovery, the production for improving poultry
Application in egg performance, raising breeder egg laying performance, chick hatching rate and rate of healthy chick.
On the basis of said program, the poultry is chicken, duck, goose, pigeon, the egg fowl of quail and kind fowl.
A kind of method for preventing poultry disease, promoting disease recovery, adds solid system prepared by the above method in feed
Agent, additive amount are 2kg/ tons；Or liquid preparation prepared by the above method is watered 2000L by daily 250mL, for 6000~8000
Ten thousand plumage egg fowls concentrate drinking-water.
A kind of method for the egg laying performance for improving poultry is shown in that egg to the superseded phase of laying eggs, adds above method system in feed
Standby solid pharmaceutical preparation, additive amount are 1kg/ tons；Or liquid preparation prepared by the above method is watered 2000L by daily 250mL, is used for
10000 plumage egg fowls concentrate drinking-water.
A kind of method for improving breeder egg laying performance, chick hatching rate and rate of healthy chick, adds above method system in feed
Standby solid pharmaceutical preparation, additive amount are 1kg/ tons；Or liquid preparation prepared by the above method is watered 2000L by daily 250mL, is used for
10000 plumage egg fowls concentrate drinking-water.
Bacillus subtilis, manufacturer：Weifang Yi Hao Bioisystech Co., Ltd, goods number：014.
Beneficial effects of the present invention
It interacts between the drug each component of the present invention, bidirectional modulation hormone secretion makes body reach most preferable reproduction
Level, the absorption of enriched nutritive substance increase calcium absorption and precipitation；Strengthen hepatic and renal function, promote toxin and Inflammatory substances point
Solution discharge；Excitating organism enzyme activity promotes being absorbed and utilized for nutriment, improves efficiency of feed utilization；Enhance human body immune function,
Anti-stress ability and premunition are improved, reduces death and culling rate；Intestinal microecology balance is maintained, reduces enterogastric diseases, is reduced
Feedstuff-egg ratio；Improve eggshell quality, improve the quality of egg, improve laying rate, extend egg-laying peak.
Radix Astragali and Radix Codonopsis are common help class Chinese medicine, and polysaccharose substance is one of its main effective active composition, have and change
The various biologicals effect such as kind immunity of organisms and enhancing premunition, is that Chinese herbal feed additive commonly uses candidate Chinese medicine.This two
In kind of Chinese medicine and animal intestine between Bifidobacteria population, there is certain synergistic effect in terms of biological activity performance, this and microorganism
Drug body intracellular metabolite is influenced related.
Isoflavones：Phytoestrogen, dual modulation balance endocrine；Improve Monitoring Ovarian Function, delay ovarian-senescence,
And then promote to lay eggs and extend ovipository cycle.
Radix Codonopsis extract, Astragalus Root P.E：Rich in nutrition, enriching yin and nourishing kidney, warm the womb of invigorating blood circulation.
Radix Astragali：Sweet, tepor, returns spleen, lung channel have tonifying Qi and lifting yang, strengthening exterior and reducing sweat, inducing diuresis for removing edema, pus draining and toxin expelling, sore life
The function of flesh；Cure mainly asthenia of pulmonosplenic qi, the sinking of qi of middle-jiao, exterior deficiency spontaneous perspiration, deficiency of vital energy oedema, sore carbuncle difficulty burst, burst for a long time and does not holds back etc..
Motherwort：It is bitter, pungent, be slightly cold, Return liver, pericardium, bladder warp have the function of invigorate blood circulation, inducing diuresis to remove edema；Cure mainly water
Swollen oliguria, lochiorrhagia, with inferior.
VE (tocopherol)：The necessary material of reproductive system normal configuration and function is maintained, it is closely related to egg laying performance
Liver, ovary, fallopian tubal have positive defencive function.
VA：Keep skin, bone, tooth, hair health growth, moreover it is possible to promote eyesight and the good development of Reproductive Performance.
VD3：For preventing and treating vitamin D deficiency.
Bacillus subtilis：Enteron aisle is improved, promotes nutrient absorption.
Through Long-term clinical and it was verified that the drug of the present invention can be obviously improved egg fowl enteron aisle, promotion nutrition digestion is inhaled
It receives, increases absorption and the deposition of calcium phosphorus, improve the quality of egg, reduce feedstuff-egg ratio, reduce the use of antibiotic.
Liquid preparation application method：
1st, laying period whole health care (superseded to laying eggs see egg) uses, and is watered 2000L by daily 250mL, is produced for 10,000 plumages
Egg fowl concentrates drinking-water.
2nd, disease or during restoring, is watered 2000L by daily 250mL, for 6000~8000 plumage egg fowls, concentrates drink
Water is used in conjunction 10 days or more.
3rd, breeder egg laying performance, chick hatching rate and rate of healthy chick are improved, 2000L is watered by daily 250mL, for 10,000 plumages
Egg fowl concentrates drinking-water.
Solid pharmaceutical preparation application method：
1st, laying period, batch mixing, feed per ton add drug 1kg of the present invention.
2nd, disease or during restoring, batch mixing, feed per ton adds drug 2kg of the present invention.
3rd, breeder egg laying performance, chick hatching rate and rate of healthy chick, batch mixing are improved, feed per ton adds drug 1kg of the present invention.
It is applicable in animal：The egg fowls such as chicken, duck, goose, pigeon, quail and kind fowl.
Description of the drawings：
Influence of the drug to the production performances of AA Breeder hens of Fig. 1, the embodiment of the present invention 2, abscissa represent classification, indulge and sit
Mark represents number.
Specific embodiment
Used term in the present invention, it is unless otherwise specified, generally usual with those of ordinary skill in the art
The meaning of understanding.
With reference to specific embodiment, and with reference to the data further detailed description present invention.Following embodiment only be
It illustrates the present invention rather than limits the scope of the invention in any way.
Embodiment 1
It is a kind of improve poultry egg laying performance drug, by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones,
Bacillus subtilis, VA, VD3, VE is prepared by weight 30: 25: 20: 0.1: 3: 3: 0.2: 0.5.
Specifically preparation method is：
1. the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis are weighed respectively
Bacterium, VA, VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, it is stirred 5~10 minutes, until
Uniformly；
3. weigh isoflavones, bacillus subtilis, VA, VD of formula ratio after crushing3, VE, be stirred 5~10 points
Clock, until uniform；
4. in 3. adding in 2., stir evenly, pack, seal to get.
Embodiment 2
It is a kind of improve poultry egg laying performance drug, by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones,
Bacillus subtilis, VA, VD3, VE is prepared by weight 15: 10: 25: 4: 0.5: 0.1: 2: 3.
Specifically preparation method is：
1. the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis are weighed respectively
Bacterium, VA, VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the isoflavones of formula ratio after crushing, add 5 times of amount Tween-80 dissolvings, add 10 times of amount dimethylacetamides
Amine is stirred until homogeneous；
3. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, 10 times of amount propylene glycol are added in, are stirred
Mixing is mixed 5~10 minutes, until uniform；
4. by the bacillus subtilis of formula ratio, VA, VD3, VE add in 3. in, stir evenly, add in purified water, until
1000mL。
Embodiment 3
It is a kind of improve poultry egg laying performance drug, by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones,
Bacillus subtilis, VA, VD3, VE is prepared by weight 20: 22: 23: 2: 2: 0.5: 2: 1.
The preparation method is the same as that of Example 1.
Embodiment 4
It is a kind of improve poultry egg laying performance drug, by Radix Codonopsis extract, Astragalus Root P.E, motherwort, isoflavones,
Bacillus subtilis, VA, VD3, VE is prepared by weight 20: 18: 22: 0.5: 1: 2: 1: 0.5.
Preparation method is the same as embodiment 2.
First, the test of pesticide effectiveness
1.1 experiment groupings
1.1.1 the drug of embodiment 1；
1.1.2 the drug of embodiment 2；
1.1.3 the drug of embodiment 3；
1.1.4 the drug of embodiment 4；
1.1.5 do not added in embodiment 3 Radix Codonopsis extract, Astragalus Root P.E, motherwort prepare drug；
1.1.6 the drug of isoflavones preparation is not added in embodiment 3；
1.1.7 the drug of bacillus subtilis preparation is not added in embodiment 3；
1.1.8 VA, VD are not added in embodiment 33, VE prepare drug；
1.1.9 blank control group.
1.2 animal experiments design
Experiment is using single factor test completely randomized design, the close sea blue brown shell layer 180 of 190 ages in days of selection health, weight
Only, 9 groups are randomly divided into, each organize 20 chickens.1~4 group is denoted as Examples 1 to 4 group using the drug of Examples 1 to 4 respectively,
Wherein, the drug of embodiment 1,3, which is added to by 1kg/ tons in basal diet, uses, and the drug occupation mode of embodiment 2,4 is by every
Its ten thousand plumage of 250mL/ is watered 2000L, collective's drinking-water per 250mL；5~8 groups add 1.1.5~1.1.8's in basal feed
Drug, additive amount are 1kg/ tons, are denoted as control group 1~4；Blank control group does not add any drug, and other conditions are consistent.Experiment
77 days periods.
1.3 Basic drawings and feeding management
Laying hen Basic drawing trophic level is with reference to NRC (1994) laying hen nutrition requirements, Basic drawing composition and battalion
Foster level is shown in Table 1.Using 3 layers of staged cage, daily illumination 16h, 5:00~21:00, morning and evening indirect labor's illumination.Freely adopt
Food and drinking-water.Routinely program prevents epidemic to laying hen and coop sterilizing.Daily 6:00 and 15:00 is fed, and 18:00 harvesting
Egg.
1 Basic drawing of table forms and trophic level (air bells dry basis)
| Raw material | Content % | Trophic level | Content % |
| Corn | 69.80 | Thick protein | 16.00 |
| Dregs of beans | 14.45 | Calcium | 3.44 |
| Mountain flour | 8.50 | Phosphorus | 0.59 |
| Peru fish meal | 4.96 | Using phosphorus | 0.42 |
| Calcium monohydrogen phosphate | 1.00 | Salt | 0.33 |
| Premix | 1.00 | Lysine | 0.83 |
| Salt | 0.20 | Methionine | 0.38 |
| Methionine | 0.09 | Methionine+cysteine | 0.63 |
| It is total | 100.00 | Metabolic energy | 11.51 |
1.4 testing indexs and method
Daily to be repeated as unit record egg number and egg size, laying rate is calculated.1 feed intake is counted per 7d, is calculated flat
Equal daily ingestion amount.It is each at the 15th, 45 day to repeat to choose 4 pieces of eggs, measure egg Egg Quality.During off-test each repeat with
Machine chooses 2 laying hens and liver, leg flesh, chest muscle portion of tissue is taken to be stored in -20 DEG C of refrigerators, for measuring Antioxidant Indexes.)
1.4.1 the measure of production performance index
Average daily gain=total feed intake/experiment number of days；
Feedstuff-egg ratio=feed intake/egg size；
Laying rate=total the number of elements of practical egg number/chicken.
1.4.2 egg quality index determining
Hangh unit, yolk color pass through multi-functional egg product analysis-e/or determining；Eggshell strength is measured using eggshell strength meter；
Shell thickness is measured using shell thickness meter.
Egg shape index=egg indulges diameter/egg transverse diameter.
1.4.3 the measure of laying hen reproductive hormone
In the 30th day of experiment, every group was randomly selected 6 chickens, wing venous blood sampling, using sodium heparin anticoagulant anti-freezing,
3000r/min centrifuges 15min, takes -20 DEG C of preservations of supernatant.Follicle-stimulating hormone (FSH), prolactin (PRL) in Laying-hen Serum,
Interstitialcellstimulating hormone (ICSH) (LH), estradiol (E2) and progesterone (P) content are measured using radioimmunoassay method.
1.4.4 the measure of ammonia and hydrogen sulfide in excrement
1d before off-test collects the fresh excreta of each group laying hen, impurities removing respectively.Weigh the excrement of every group of identical weight
Just, it is loaded on respectively in band plug vial, sealing room temperature fermentation 3d.The fermentation gas of each group excrement is extracted after fermentation respectively, is detected
The content of ammonia and hydrogen sulfide gas.Wherein ammonia is measured using reagent colorimetric method, and hydrogen sulfide is divided using methylene blue
Photometry carries out analysis measure.
1.4.5 the measure of sero-immunity index
At first day 8 after the test:00, as unit of repetition, each to repeat to randomly select 10 chickens, vein is adopted under wing
Blood collects 5mL with solidifying pipe is promoted, and after standing 30min, 10min, 0.5~1.0mL of Aspirate supernatant, injection are centrifuged in 3000r/min
In 1.5mL centrifuge tubes, label group, date, it is placed in -20 DEG C of freezen protective test serum immune indexes.
1.4.6 Antioxidant Indexes measure
Liver, leg flesh, malonaldehyde (MDA) content of chest muscle and superoxide dismutase (SOD), glutathione peroxidase
Enzyme (GSH-PX) activity is built up Bioengineering Research Institute by Nanjing and is provided using kit measurement, kit.
1.5 data statistic analysis
One-way analysis of variance (onewayANOVA) is carried out using SPSS13.0, as a result with " mean+SD " table
Show, and each group of data is handled with DuncanShi multiple comparison graphs.
2nd, result of the test
Influence of 2.1 drugs of the present invention to performance in layers
Influence of the drug of the present invention to performance in layers is as shown in table 2：
Influence of the table 2 to performance in layers
As can be seen from Table 2, embodiment 1, the average daily gain of 2,3 and 4 groups of laying hens are slightly lower compared with blank control group, each group
The average daily gain of laying hen is not much different, no significant difference；Compared with blank control group, the laying rate of each group laying hen has significantly
It improves, wherein, Examples 1 to 4 group laying rate of laying hen is significantly higher than other control groups, and the laying rate of 3,4 groups of laying hens of embodiment is high
In 1,2 group of embodiment；1~4 group of egg size of Examples 1 to 4 group and control group, compared with blank control group, there is weightening, wherein,
The egg size of Examples 1 to 4 group is higher than 1~4 group of control group, and the egg size of 3,4 groups of laying hens of embodiment is higher than 1,2 group of embodiment；Egg material
Than, compared with blank control group, embodiment each group reduces, wherein, the feedstuff-egg ratio of 3,4 groups of laying hens of embodiment, which is substantially less than, to be compareed
Group (P<0.05).
Influence of 2.2 drugs of the present invention to laying hen eggshell quality
Influence of the drug of the present invention to laying hen eggshell quality is as shown in table 3：
Influence of the table 3 to laying hen eggshell quality
Each group eggshell relative mass is higher than control group, but the not notable (P of difference as can be seen from Table 3>0.05)；Embodiment 1
~4 groups of rate of broken eggs are significantly lower than control group (P<0.05) without significant difference (P, but between Examples 1 to 4 group>0.05).Illustrate to add
After pharmaceutical composition of the present invention, rate of broken eggs reduces, and eggshell quality improves.
Influence of 2.3 drugs of the present invention to Egg Production of Laying Hens quality
Influence of the drug of the present invention to Egg Production of Laying Hens quality is as shown in table 4.
As can be seen from Table 4, yolk color, the 15th day, embodiment each group yolk color was above control group but without notable
Sex differernce (P>0.05), the 45th day, embodiment each group yolk color was above control group, was especially more than 1,2 group of control；
Eggshell strength, the 15th day, embodiment each group eggshell strength was shown higher than control each group, 3,4 groups of eggshell strengths of embodiment
It writes higher than control group (P<0.05), the 45th day, embodiment 1,2,3 and 4 groups of yolk colors were significantly higher than control group, embodiment 3,4
Group eggshell strength highest, there was no significant difference between embodiment each group (P>0.05)；
Shell thickness and egg shape index, at the 15th day, the 45th day, there was no significant difference between each group (P>0.05)；
Yolk ratio, at the 15th day, the 45th day, embodiment each group yolk ratio was above control group, especially embodiment 3,4
The yolk ratio of group is maximum.
After result of the test shows addition drug of the present invention, quality of laying eggs is can obviously improve, improves the quality laid eggs.
The quality of egg not only includes the presentation quality of egg, internal indicator such as hangh unit, yolk color, yolk ratio
Deng the quality of also decision egg.Hangh unit is the important indicator for reflecting egg freshness, and egg is fresher, and albumen is more thick
And thickness is bigger, hangh unit is bigger therewith, the normal variation ranging from 75~85 of general Fresh Egg hangh unit, some
Up to 90.This later stage, the hangh unit of egg are most of in normal range (NR) and the hangh unit of embodiment each group compares
It is bigger according to organizing, illustrate that drug of the present invention is playing the role of maintaining egg fresh to a certain degree.
Influence of 4 drug of the present invention of table to Egg Production of Laying Hens quality
In this experiment, after adding drug of the present invention in feed, shell thickness is improved, and the normal thickness of eggshell is 0.20
~0.48mm, eggshell strength have increased trend；Radix Astragali, isoflavones ingredient are added in drug of the present invention, increases yolk
Color and luster；And the ratio of yolk increases, and illustrates that the nutritive value of egg is promoted.
Influence of 2.4 drugs of the present invention to laying hen reproductive hormone
Influence of the drug of the present invention to laying hen reproductive hormone is shown in Table 5.
Influence of 5 drug of the present invention of table to laying hen reproductive hormone
As shown in Table 5, after adding drug of the present invention in feed, hence it is evident that reduce PRL contents in serum and increase in serum
The content of FSH, LH, E2 and P, embodiment 3,4 effects are most apparent, compared with blank control group, have significant difference (P ＜
0.05)。
Influence of 2.5 drugs of the present invention to laying hen digestic property
Influence of the drug of the present invention to laying hen digestic property is shown in Table 6.
Influence of 6 drug of the present invention of table to laying hen digestic property
As shown in Table 6, after adding drug of the present invention, the emission of ammonia is below compareing in embodiment group laying hen fermentation excrement
The emission of group, wherein 3,4 groups of ammonias of embodiment does not reduce 22.26%, 22.10% than control component, significant difference (P<
0.05)；The emission of Examples 1 to 4 each group hydrogen sulfide is reduced than control group, and wherein 3,4 groups of hydrogen sulfide contents of embodiment are shown
Writing reduces, other each groups there was no significant difference (P>0.05).
Influence of 2.6 drugs of the present invention to Laying-hen Serum immune indexes
Influence of the drug of the present invention to Laying-hen Serum immune indexes is shown in Table 7.
Influence of 7 drug of the present invention of table to Laying-hen Serum immune indexes
7 experimental result of table shows that there was no significant difference to serum IgA content with comparative example each group for embodiment each group；Implement
3,4 groups of example significantly improves serum IgM content (P<0.05), other groups are without significant difference；3,4 groups of embodiment significantly reduces
IgG content (P<0.05), other groups are influenced without conspicuousness.Embodiment each group ALB and TP are higher than control group, 3,4 groups of embodiment
Significantly improve ALB contents.
The influence of 2.7 pairs of Liver of Laying Hens, muscle Antioxidant Indexes
Influence of the drug of the present invention to Liver of Laying Hens, muscle Antioxidant Indexes is shown in Table 8.
GSH-Px activity is followed successively by leg flesh>Chest muscle>Liver, liver, chest muscle between each group, leg flesh GSH-Px activity inequality
Different not significantly (P>0.05).Liver, chest muscle, the not notable (P of leg flesh SOD activity difference between each group>0.05).Embodiment is each
The liver of group, chest muscle MDA contents have reduction, but the not notable (P of difference compared with control group>0.05)；Embodiment each group leg flesh MDA contents
There are reduction, but the not notable (P of difference compared with control group>0.05)；GSH-Px, SOD of embodiment 3,4 groups of livers, chest muscle and leg flesh
Activity increases, and MDA contents reduce.
Influence of 8 drug of the present invention of table to Liver of Laying Hens, muscle Antioxidant Indexes
2nd, influence of the drug of the present invention to performance in layers is added in daily ration
1st, materials and methods
The blue laying hen 120 in 24 week old sea that development is normal, healthy is selected in this experiment, and 47 week old off-tests are randomly divided into
2 groups of test group and control group each organize three repetitions, each repeat 20 laying hens.Test group is added in basal diet
The drug of 0.1% embodiment of the present invention 1；Control group basal diet does not add any drug；Research drug of the present invention is to extra large blue egg
The influence of chicken egg-laying peak production performance.Its composition of basal diet and nutritional ingredient are shown in Table 1.Test chicken is three layers of cage, often
3, cage is freely eaten and drinks water, routinely carries out feeding management.Experimental period, is by 47 week old, totally 168 days experimental period, in Shandong
Certain farm carries out.Other conditions are completely the same, routinely carry out.Manual material feeding, free choice feeding, free water.Observation daily
Record often repeats egg number, egg size, unqualified egg number and chicken and extremely washes in a pan situation and feed consumption rate.
On-test, at the end of, carries out calculating feed consumption rate, average egg weight, feedstuff-egg ratio, hair as unit of repeating groups respectively
The indexs such as sick rate, survival rate, breakage rate.
9 basal diet of table forms and nutritional ingredient
| Ingredient | Content (%) | Nutritional ingredient | Numerical value |
| Corn | 61.0 | Metabolic energy (Mcal/kg) | 2.61 |
| Dregs of beans | 20.0 | Crude protein (%) | 16.70 |
| Rapeseed meal | 4.0 | Calcium (%) | 3.60 |
| Cotton dregs | 4.0 | Total phosphorus (%) | 0.50 |
| Mountain flour | 8 | Methionine (%) | 0.31 |
| Premix | 3 |
2nd, result and analysis
2.1 pairs of laying hen feeding experiment reports refer to table 10, table 11.
By the data in table 10 it is found that after adding 0.1% embodiment, 1 drug in the orchid egg feedstuff of sea, 32~35 week old, 36
~39 week old, 40~43 week old, 44~47 week old laying rate test groups are higher than control group, significant difference (P<0.05).Wherein, it is extra large
After adding 1 drug of embodiment in blue egg feedstuff, 40~43 weeks test group laying rate are 90.24%, control group laying rate is
82.74%, test group laying rate is higher than control group by 7.5%, significant difference (P<0.05).Embodiment is added in extra large orchid egg feedstuff
After 1 drug, 44~47 weeks test group laying rate are 88.19%, control group laying rate is 80.22%, and test group laying rate compares
According to high by 7.97%, the significant difference (P of group<0.05).The average egg weight of test group is slightly above control group, each experimental stage each group difference
Not significantly.
The influence that table 10 adds up laying rate of laying hen, egg size, day egg number
11 embodiment of table, 1 drug can influence extra large blue laying hen feedstuff-egg ratio, death and culling rate
| Group | Feedstuff-egg ratio | Death and culling rate % |
| Test group | 1.12±0.01 | 0.16±0.01 |
| Control group | 1.29±0.02 | 0.38±0.01 |
By the data in table 11 it is found that adding 0.1% embodiment, 1 drug in orchid 24 week old of laying hen to 47 week old feeds of sea
Afterwards, feedstuff-egg ratio test group reduces 0.17 than control group, significant difference (P<0.05), death and culling rate reduces by 57.9%, significant difference (P<
0.05), illustrate after adding drug of the present invention, feedstuff-egg ratio reduces, and death and culling rate reduces, cost reduction, and income improves.
3rd, influence of the drug of the present invention to breeder production performance
1st, materials and methods
1000 plumage of AA Breeder hens with 40 week old of building henhouse is selected in this experiment, is divided into 2 groups, i.e. test group and control
Group, each 500 plumage, the liquid preparation that test group is prepared using embodiment 2, occupation mode are daily ten thousand plumages of 250mL/, are converted per 250mL
Water 2000L, collective's drinking-water.Control group does not add any drug, other experimental conditions are consistent.Measure 8 weeks periods.
2nd, result and analysis
Influence of the drug of the embodiment of the present invention 2 to the production performance of AA Breeder hens is as shown in Figure 1：
As shown in Figure 1, total egg number of AA Breeder hens can be significantly improved using the drug of the embodiment of the present invention 2, and
Qualified hatching egg number, fertile egg number are also significantly greater than control group；Gone out using what the AA Breeder hens of the drug of the embodiment of the present invention 2 were laid eggs
Young number and strong young number are also dramatically increased relative to control group.This illustrates that the drug of the present invention can improve the productivity of AA Breeder hens
Energy.
4th, influence of the drug of the present invention to breeding layer chicken economic benefit
1st, materials and methods
The blue brown shell layer 600 in sea of egg is shown in this experiment selection, is randomly divided into 2 groups, test group and control group, every group 300
Plumage.The liquid preparation that test group is prepared using embodiment 2, occupation mode are daily ten thousand plumages of 250mL/, and 2000L is watered per 250mL,
Collective drinks water.Control group does not add any drug, other experimental conditions are consistent.Test period from see egg to eliminate.Record every group
Egg production, average egg weight, inferior egg number, egg-laying peak.Calculate each group drug use cost, total economic benefit.
2nd, experiment and analysis
Influence of the drug of the embodiment of the present invention 2 to breeding layer chicken economic benefit is as shown in table 12.
Analysis of the table 12 to breeding layer chicken Efficiency
The data of table 12 are under equal rearing conditions, and addition 2 drug of embodiment compares obtained number with un-added
According to.By the data of table 12 it is found that
1st, the drug of the addition embodiment of the present invention 2 can make 20 pieces/of AA Breeder hens egg production fecund, and inferior egg reduces 10
Piece/only, total fecund go out qualified 30 pieces of egg product/only；
2nd, the drug of the addition embodiment of the present invention 2 can make AA Breeder hens average egg weight increase by 1.5 grams, be laid eggs with laying hen all one's life
320 pieces of calculating, Total egg weight increase by 320 × 1.5 grams=480 grams；
3rd, the drug of the addition embodiment of the present invention 2 can make AA Breeder hens egg focus on 65 grams -72 grams/piece, 30 pieces of eggs
Weight be 2000 grams or so；
4th, the drug of the addition embodiment of the present invention 2 can make AA Breeder hens that fecund be added up to go out weight of egg and amount to 2500 grams of (5 cities
Jin), according to the market price at 15 yuan or so.
5th, the drug of the addition embodiment of the present invention 2 can make AA Breeder hens count drug in using reducing 2 yuan/, subtract use
1.4 yuan of cost/only, add up to benefit at 15-20 yuan/.
5th, influence of the present invention to egg dove laying rate and quality of laying eggs
1st, materials and methods
In clinical trial, 400 50 week old are selected through one week observation egg production is substantially close, healthy disease-free, weight size base,
This consistent egg dove, 10 days preliminary trial periods, after adjustment dove feed intake only, laying rate no significant difference, start formal test.At random
It is divided into 4 groups, every group 100, sets 5 repetitions in group, it is each to repeat 20.
Feeding management routinely carries out：Using conventional three layers of cage, per three pigeons of cage, two cages share a water fountain.
In a manner that early, evening supplement artificial lighting and natural lighting on daytime are combined, artificial lighting+natural lighting 16 hours.Dovecote
Using gravity-flow ventilation+force ventilation, mash feed is fed, is freely eaten, drinking-water.The morning 9 twice are fed daily:00 and afternoon
17:00 each feeding is primary.Every morning 12:00, afternoon 17:30 respectively receive an egg.Every 2 days clear one time pigeon dung, weekly to dovecote
A spraying disinfection is carried out, is routinely immunized, observes the health condition and record of pigeon daily.
Wherein, the 1st, the 3 group of drug that the embodiment of the present invention 1,3 is added in basal diet, additive amount 0.1%；2nd group
Using 2 groups of drug of embodiment, occupation mode is daily ten thousand plumages of 250mL/, and 2000L, collective's drinking-water are watered per 250mL.Control group
Any drug is not added in the basal diet and drinking water of feeding.Basal diet is wheat bran, maize pulp, oyster shell whiting, cotton dregs, rice
Chaff, dregs of beans, rapeseed meal, methionine, calcium carbonate, salt mixture.Wherein, 7 parts by weight of wheat bran, 60 parts by weight of maize pulp, oyster shell whiting 5
Parts by weight, 7 parts by weight of cotton dregs, 25 parts by weight of rice bran, 15 parts by weight of dregs of beans, 6 parts by weight of rapeseed meal, 3 parts by weight of methionine, calcium carbonate
3 parts by weight, 2 parts by weight of salt.The daily number of laying eggs of record, livestock on hand dove number, and laying rate is calculated as follows (including broken
Damage egg).
Laying rate (%)=(daily egg number/livestock on hand dove number) × 100%.
2nd, result and analysis
Influence of the drug of the present invention to egg dove laying rate and protein content is shown in Table 13.
Influence of 13 Chinese medicine additive of table to egg dove laying rate and protein content
As shown in Table 13, the 1st week test group and control group difference is not notable；Test group laying rate and egg since the 2nd week
Bai Hanliang is higher than control group；Test group laying rate significantly improved since the 3rd week, the 4th week, and control group is substantially in same water
It is fluctuated on horizontal line, in contrast, the test group laying rate of three embodiments is apparently higher than control group, and significant difference；From experiment
From the point of view of full period, test group average egg production is respectively 9.41%, 10.10% and 9.56%, than the average production of control group 6.86%
Egg rate is 2.55~3.24 percentage points high；Especially the 11.18% of embodiment 3 the tenth week, 6.78% than control group is higher by
4.40 percentage points, protein content 18.72% to 13.51% is higher by 5.21 percentage points.It can be seen that the drug of the present invention can
To dramatically increase egg dove age in days and laying rate.Laying rate from before 6.7% or so (about 15 days one) till now 11%
Left and right (general 9 days one), is obviously improved.Can also increase percent protein (before 13.48%, it is present 18.60%), pigeon
Survival rate increase by 80%, the speed of growth is significantly accelerated, 25 days/600 grams of average weight.
6th, safety experiment
Acute toxicity testing：Application mouse 175, half male and half female, 21~29g of weight carry out acute toxicity testing.Mouse
5 groups, i.e. control group, 1 administration group of embodiment, 2 administration group of embodiment, 3 administration group of embodiment, 4 administration group of embodiment are randomly divided into,
Traditional Chinese powder medicine one prepared by the embodiment of the present invention 1,3 is dissolved in water (a concentration of 15.54g lifes by fasting 12 hours before experiment
Medicine/mL, maximum concentration) gavage, gavage volume is 5mL/kg (i.e. unit dosage form is 77.7 crude drugs/kg)；The reality of the present invention
The liquid preparation of the preparation of example 2,4 is applied, is 77.7 crude drugs/kg gastric infusions according to unit dosage form；Control group gives equivalent life
Manage brine；It is administered 2 times within one day, delivery time 6 hours is observed continuously 14 days, and the toxicity for recording mouse is anti-after administration
Should and death toll.The experimental results showed that：Compared with the control group, mouse has no notable difference after administration, and experiment is observed continuously 14 days,
Mouse systemic situation, diet, drinking-water, body weight increase are normal.The powder LD50 of the Mouse oral gavage present invention>77.7 crude drug/
Kg, daily maximum dosage-feeding are 155.4 crude drugs/kg/ days.The Chinese medicine clinical application amount of the present invention is 2g crude drugs/day/chicken, is grown up
For laying hen weight in terms of 1.8kg, average dosage is 1.111g crude drugs/kg/ days.By batheroom scale：(average weight is with 25g for mouse
Meter) dosis tolerata of Chinese medicine of the oral administration gavage present invention is 140 times of quantity.Therefore the Chinese medicine acute toxicity of the present invention is low,
Clinical application safety.
Long term toxicity test：The liquid preparation of Chinese medicine embodiment 1 of the present invention, 3 solid pharmaceutical preparations and embodiment 2,4, to mouse
By 4.82,9.32 and 17.42g crude drugs/kg continuous uses 15 weeks (1.0mL/100g weight, 2 times a day) and after being discontinued 3 weeks, knot
Fruit shows：Chinese medicine of the present invention is to the hair of mouse, behavior, stool and urine, weight, organ weights, blood picture, hepatic and renal function, blood glucose, blood
The indexs such as fat have no significant effect, internal organs naked eyes without find it is abnormal variation and histological indications show medication 15 weeks and
It is discontinued after 3 weeks, Organs of Mice nothing is substantially change.Illustrate Chinese medicine of the present invention to small toxicity after mouse long-term administration, after drug withdrawal
Also without abnormal reaction, application is safe.
The above described is only a preferred embodiment of the present invention, being not that the invention has other forms of limitations, appoint
What those skilled in the art changed or be modified as possibly also with the technology contents of the disclosure above equivalent variations etc.
Imitate embodiment.But it is every without departing from technical solution of the present invention content, technical spirit according to the present invention is to above example institute
Any simple modification, equivalent variations and the remodeling made still fall within the protection domain of technical solution of the present invention.
Claims (10)
1. a kind of drug for improving poultry egg laying performance, it is characterised in that：By Radix Codonopsis extract, Astragalus Root P.E, motherwort, big
Beans isoflavones, bacillus subtilis, VA, VD3, VE is by weight 15~30: 10~25: 20~25: 0.1~4: 0.5~3: 0.1
~3: 0.2~2: 0.5~3 are prepared.
2. the drug of poultry egg laying performance is improved according to claim 1, it is characterised in that：It is carried by Radix Codonopsis extract, Radix Astragali
Take object, motherwort, isoflavones, bacillus subtilis, VA, VD3, VE by weight 20: 22: 23: 2: 2: 0.5: 2: 1 prepare
It forms.
3. the drug according to claim 1 or claim 2 for improving poultry egg laying performance, it is characterised in that：The dosage form of the drug is
Solid pharmaceutical preparation or liquid preparation.
It is 4. special according to the preparation method of any one of claims 1 to 3 solid pharmaceutical preparation for improving poultry egg laying performance drug
Sign is：Step is：
1. weigh respectively the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis,
VA、VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, it is stirred 5~10 minutes, until equal
It is even；
3. weigh isoflavones, bacillus subtilis, VA, VD of formula ratio after crushing3, VE, be stirred 5~10 minutes, until
Uniformly；
4. in 3. adding in 2., stir evenly, pack, seal to get.
It is 5. special according to the preparation method of any one of claims 1 to 3 liquid preparation for improving poultry egg laying performance drug
Sign is：Step is：
1. weigh respectively the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort, isoflavones, bacillus subtilis,
VA、VD3, VE, smash it through respectively 120 mesh sieve；
2. weighing the isoflavones of formula ratio after crushing, add 5 times of amount Tween-80 dissolvings, add 10 times of amount dimethylacetylamides, stir
It mixes to uniform；
3. weighing the Radix Codonopsis extract of formula ratio, Astragalus Root P.E, motherwort after crushing, 10 times of amount propylene glycol are added in, stirring is mixed
It closes 5~10 minutes, until uniform；
4. by the bacillus subtilis of formula ratio, VA, VD after crushing3, VE add in 3. in, stir evenly, add in purified water, until
1000mL。
6. 4 or 5 the method for claim prepare raising poultry egg laying performance drug in poultry disease or disease recovery, carry
The egg laying performance of high poultry improves application in breeder egg laying performance, chick hatching rate and rate of healthy chick.
7. application according to claim 6, it is characterised in that：The poultry is chicken, duck, goose, pigeon, quail are laid eggs
Fowl and kind fowl.
A kind of 8. method for preventing poultry disease, promoting disease recovery, it is characterised in that：Claim 4 is added in feed to make
Standby solid pharmaceutical preparation, additive amount are 2kg/ tons；Or liquid preparation prepared by claim 5 method is watered by daily 250mL
2000L for 6000~80,000,000 plumage egg fowls, concentrates drinking-water.
A kind of 9. method for the egg laying performance for improving poultry, it is characterised in that：See that egg is superseded to laying eggs, right is added in feed
It is required that 4 solid pharmaceutical preparations prepared, additive amount is 1kg/ tons；Or liquid preparation prepared by claim 5 method is converted by daily 250mL
Water 2000L for 10,000 plumage egg fowls, concentrates drinking-water.
A kind of 10. method for improving breeder egg laying performance, chick hatching rate and rate of healthy chick, it is characterised in that：It is added in feed
Solid pharmaceutical preparation prepared by claim 4, additive amount are 1kg/ tons；Or liquid preparation prepared by claim 5 method is by daily
250mL is watered 2000L, for 10,000 plumage egg fowls, concentrates drinking-water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810002615.6A CN108185137A (en) | 2018-01-02 | 2018-01-02 | A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810002615.6A CN108185137A (en) | 2018-01-02 | 2018-01-02 | A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108185137A true CN108185137A (en) | 2018-06-22 |
Family
ID=62588150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810002615.6A Pending CN108185137A (en) | 2018-01-02 | 2018-01-02 | A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108185137A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109924367A (en) * | 2019-04-04 | 2019-06-25 | 河南鑫牧生物科技有限公司 | A kind of feed addictive and preparation method thereof improving egg fowl physiological function |
| CN110367381A (en) * | 2019-08-09 | 2019-10-25 | 广东省农业科学院动物科学研究所 | A kind of laying duck drinking water additive, laying duck drinking-water formula and its preparation method and application |
| CN112931720A (en) * | 2021-03-04 | 2021-06-11 | 安佑生物科技集团股份有限公司 | Feed additive for improving salpingitis of laying fowls, preparation method and application thereof |
| CN115053865A (en) * | 2022-06-27 | 2022-09-16 | 四川省畜牧科学研究院 | Method for breeding new variety of high-yield laying hens |
| RU2792119C1 (en) * | 2022-06-08 | 2023-03-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" | Method for assessing the egg production of chickens |
| CN115918804A (en) * | 2022-11-23 | 2023-04-07 | 成都大帝汉克生物科技有限公司 | Regulator for improving egg laying performance and egg quality of laying hens and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1312370A1 (en) * | 2001-11-16 | 2003-05-21 | Iijima Corporation | Composition comprising dried whole egg for treating hepatitis |
| CN104825718A (en) * | 2015-04-16 | 2015-08-12 | 山东宝来利来生物工程股份有限公司 | Chinese medicine probiotic compound preparation and preparation method thereof for poultry ovarian maintenance |
| CN105535700A (en) * | 2016-01-18 | 2016-05-04 | 山东迅达康生物科技有限公司 | Medicinal composition for improving laying rate and hatching rate of laying poultry and breeding poultry, and preparation method thereof |
| CN105851714A (en) * | 2016-06-17 | 2016-08-17 | 安庆市皖宜季牛水产养殖有限责任公司 | Antibacterial, disease-resisting and anti-hypoxia growth-promoting feed of mandarin fish |
| CN107156512A (en) * | 2017-05-25 | 2017-09-15 | 山东惠泽农牧科技有限公司 | Plant the mixed feed of duck egg-laying peak |
-
2018
- 2018-01-02 CN CN201810002615.6A patent/CN108185137A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1312370A1 (en) * | 2001-11-16 | 2003-05-21 | Iijima Corporation | Composition comprising dried whole egg for treating hepatitis |
| CN104825718A (en) * | 2015-04-16 | 2015-08-12 | 山东宝来利来生物工程股份有限公司 | Chinese medicine probiotic compound preparation and preparation method thereof for poultry ovarian maintenance |
| CN105535700A (en) * | 2016-01-18 | 2016-05-04 | 山东迅达康生物科技有限公司 | Medicinal composition for improving laying rate and hatching rate of laying poultry and breeding poultry, and preparation method thereof |
| CN105851714A (en) * | 2016-06-17 | 2016-08-17 | 安庆市皖宜季牛水产养殖有限责任公司 | Antibacterial, disease-resisting and anti-hypoxia growth-promoting feed of mandarin fish |
| CN107156512A (en) * | 2017-05-25 | 2017-09-15 | 山东惠泽农牧科技有限公司 | Plant the mixed feed of duck egg-laying peak |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109924367A (en) * | 2019-04-04 | 2019-06-25 | 河南鑫牧生物科技有限公司 | A kind of feed addictive and preparation method thereof improving egg fowl physiological function |
| CN110367381A (en) * | 2019-08-09 | 2019-10-25 | 广东省农业科学院动物科学研究所 | A kind of laying duck drinking water additive, laying duck drinking-water formula and its preparation method and application |
| CN112931720A (en) * | 2021-03-04 | 2021-06-11 | 安佑生物科技集团股份有限公司 | Feed additive for improving salpingitis of laying fowls, preparation method and application thereof |
| RU2792119C1 (en) * | 2022-06-08 | 2023-03-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" | Method for assessing the egg production of chickens |
| CN115053865A (en) * | 2022-06-27 | 2022-09-16 | 四川省畜牧科学研究院 | Method for breeding new variety of high-yield laying hens |
| CN115053865B (en) * | 2022-06-27 | 2023-04-14 | 四川省畜牧科学研究院 | Method for breeding new variety of high-yield laying hens |
| CN115918804A (en) * | 2022-11-23 | 2023-04-07 | 成都大帝汉克生物科技有限公司 | Regulator for improving egg laying performance and egg quality of laying hens and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108185137A (en) | A kind of drug, preparation method and application for improving poultry egg laying performance and improving quality of laying eggs | |
| CN101554206B (en) | Composite plant feed additive | |
| CN1868302B (en) | Chinese herb medicine additive for chicken feed | |
| CN103598426B (en) | For improving feed addictive and the feed of growth performance of chicks | |
| CN103636932B (en) | Feedstuff for young birds at mouth-open period and preparation method and application thereof | |
| CN107173626A (en) | Chinese medicine egg feedstuff and preparation method thereof | |
| CN103519009B (en) | Healthcare sand for pigeons | |
| CN103598405B (en) | For improving the feed of laying hen Egg Quality | |
| CN104905027A (en) | Quail feed capable of enhancing immunity | |
| CN102078522A (en) | Chinese medicine composition for treating enterovirus syndrome in chicken | |
| CN103039725B (en) | Health-care chick starter feed | |
| CN105519816B (en) | A kind of additive improving laying hen anti-stress ability | |
| CN106036075A (en) | Green and environment-friendly milk cow feed additive | |
| CN106266101A (en) | A kind of veterinary Chinese medicinal composition and its production and use | |
| CN105533255A (en) | Application of Chinese herbal medicine feed additive | |
| CN103598437A (en) | Feed for improving egg laying capacity of layer chickens | |
| CN108771016A (en) | One boar Chinese herbal feed additive and its application | |
| CN102783568B (en) | Feed additive | |
| CN102166255B (en) | Chinese medicinal composition for increasing chicken production performance | |
| CN101715893A (en) | Pure natural piglet immunological enhancement feed additive and application thereof | |
| CN106135748A (en) | A kind of fowl Chinese herbal medicine microorganism composite feed additive | |
| CN103315177B (en) | Rex rabbit feed | |
| CN111937809B (en) | Breeding method of nutritious chicken and feed formula used by breeding method | |
| CN107348171A (en) | One kind improves soft-shelled turtle survival rate feed easy to digest | |
| CN107080090A (en) | A kind of black-bone chicken health-care feed formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180622 |
|
| RJ01 | Rejection of invention patent application after publication |